Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria
A Randomised, Multi-Centre, Phase II, Dose-ranging Clinical Study to Assess the Safety and Efficacy of Fixed Dose, Orally Administered Pyronaridine and Artesunate (3:1) in Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria
Sponsor: Medicines for Malaria Venture
Listed as NCT01594931, this PHASE2 trial focuses on Plasmodium Falciparum Malaria and remains completed. Sponsored by Medicines for Malaria Venture, it has been updated 9 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Oct 2021 — Dec 2021 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Completed PHASE2
-
May 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jun 2018 — May 2020 [monthly]
Completed PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE2
First recorded
Jul 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medicines for Malaria Venture
- Shin Poong Pharmaceutical Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .